BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT – Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $7.53 and last traded at $7.4950, with a volume of 195346 shares. The stock had previously closed at $7.78.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on the company. Canaccord Genuity Group assumed coverage on BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $23.00 price target for the company. Wall Street Zen cut shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright raised their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BridgeBio Oncology Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $25.00.
Check Out Our Latest Stock Analysis on BBOT
BridgeBio Oncology Therapeutics Stock Performance
BridgeBio Oncology Therapeutics (NASDAQ:BBOT – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. As a group, sell-side analysts forecast that BridgeBio Oncology Therapeutics, Inc will post -2.32 earnings per share for the current year.
Institutional Investors Weigh In On BridgeBio Oncology Therapeutics
Several large investors have recently modified their holdings of BBOT. Geode Capital Management LLC raised its holdings in shares of BridgeBio Oncology Therapeutics by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after buying an additional 20,385 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at about $1,185,000. BIT Capital GmbH purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at about $313,000. CIBC Private Wealth Group LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at about $63,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at about $930,000. 54.89% of the stock is owned by institutional investors and hedge funds.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.
BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.
Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.
Featured Stories
- Five stocks we like better than BridgeBio Oncology Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for BridgeBio Oncology Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Oncology Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
